TD Cowen raised the firm’s price target on HCA Healthcare (HCA) to $380 from $361 and keeps a Buy rating on the shares. The firm updated its model following its quarterly report and noted management will seize the enahnaced subsidy headwind in Q4 earnigs whxi has now become the focal point and controversy for investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target lowered to $401 from $404 at RBC Capital
- HCA Healthcare: Hold Rating Amid Mixed Signals and Policy Uncertainty
- HCA Healthcare downgraded to Peer Perform from Outperform at Wolfe Research
- HCA Healthcare price target lowered to $390 from $416 at Barclays
- Hold Rating for HCA Healthcare Amid Strong Q2 Results and Future Headwinds Concerns